New Stock News | Maiwei Biotechnology (688062.SH) applies for a second listing on the Hong Kong Stock Exchange

According to the disclosure of the Hong Kong Stock Exchange on March 25th, Maiwei (Shanghai) Biotechnology Co., Ltd. (Maiwei Biotech (688062.SH)) has submitted its listing application to the main board of the Hong Kong Stock Exchange. CITIC SEC and HAITONG INT'L are the joint sponsors. This is the company's second submission to the Hong Kong Stock Exchange. According to the prospectus, Maiwei Biotech's core product 9MW2821 is an antibody-drug conjugate targeting the Nectin cell adhesion molecule 4. In addition, the company has established a pipeline product portfolio consisting of over 13 different drug assets.